Saturday, March 18, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Featured News

Healthcare-Associated Spread of MERS-CoV

by Global Biodefense Staff
December 4, 2014
MERS Virus Protein Particles

Researchers have identified gaps in infection control as a major culprit in all eleven published cases involving healthcare-associated transmission of Middle East respiratory syndrome coronavirus (MERS-CoV).

The findings were recently published in the American Journal of Infection Control.

Researchers from the Hellenic Center for Disease Control and Prevention in Athens, Greece, reviewed 252 papers on MERS-CoV, ultimately narrowing their focus to 10 studies covering 11 cases of possible or confirmed healthcare-associated transmission of the virus, which causes severe respiratory disease with a high fatality rate.

Although the majority of cases have occurred in Middle Eastern countries since the virus first appeared in 2012, there have also been documented cases in Europe, Africa, and the United States. Two out of three affected patients have been male, with a median age of 49 years.

Healthcare workers (HCW), particularly nurses, are at heightened risk of acquiring MERS-CoV from infected patients from the environment and also through person-to-person contact. The virus has been shown to survive for at least 48 hours on hospital surfaces, and is transmissible through vomit and diarrhea, which present in roughly one-third of cases. MERS-CoV has been detected for up to 16 days in respiratory specimens and stool, and up to 13 days in urine.

“Patients with confirmed or suspected MERS-CoV infection should be cared for under contact and droplet precautions until testing results,” the authors stress. According to WHO guidelines, this includes wearing a high protection mask (e.g., N95 respirator), eye goggles, gowns, and gloves during aerosol-generating procedures. The U.S. Centers for Disease Control and Prevention recommends use of respirator masks when in contact with any suspected or confirmed MERS-CoV patient.

Read the study: Middle East respiratory syndrome coronavirus: Implications for health care facilities.

Tags: BiosafetyCoronavirusEmerging ThreatsMERS-CoV

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
NIH Grant Awarded to Study Evolution of Lyme Disease Bacteria in Deer Ticks
Pathogens

NIH Grant Awarded to Study Evolution of Lyme Disease Bacteria in Deer Ticks

December 7, 2022
Bat Virus Receptor Studies Vital to Predict Spillover Risk
Pathogens

Bat Virus Receptor Studies Vital to Predict Spillover Risk

December 7, 2022
2022 Oral Rabies Vaccine Efforts Underway in Eastern United States
Pathogens

2022 Oral Rabies Vaccine Efforts Underway in Eastern United States

August 8, 2022
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy